Phase 4 Completed N=35 Supportive Care

Counseling Among Gender Diverse Adolescents Who Use Depot Medroxyprogesterone

Gender Dysphoria, Adolescent

Source: ClinicalTrials.gov NCT05726903 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Feb 2026

Primary outcomePrimary: Number of Participants Satisfied With Self-Administered DMPA at Initiation — 17 Participants

◆ Published Evidence

No publication linked

No peer-reviewed publication reporting this trial's results has been linked yet. This can indicate results are unpublished — a known publication-bias signal. We re-check periodically.

Summary

Recommendations regarding contraceptive counseling and reproductive health differ amongst transgender and gender diverse (TGD) youth compared to cis-gender youth. Limited existing literature demonstrates the need for contraceptive counseling that moves beyond cis- and heteronormative assumptions that start with pregnancy prevention and address concerns at the intersection of gender identity. The Investigator's qualitative study will focus on creating best practices regarding equitable contraceptive counseling for TGD youth. The Investigator will recruit transgender youth who are assigned female at birth, and currently or interested in using depo medroxyprogesterone (DMPA). Through focus groups and semi-structured interviews, the investigator hopes to guide providers in creating best practices and more equitable contraceptive counseling for TGD youth and measure satisfaction of DMPA in TGD youth.

Outcome Measures

Outcome	Result	p-value
PRIMARY Number of Participants Satisfied With Self-Administered DMPA at Initiation	17	—
PRIMARY Number of Participants Satisfied With DMPA in an Office Setting	4	—

Eligibility Criteria

Inclusion Criteria

between the ages of 15-21,
currently receiving care at one of the clinic sites, assigned female at birth, identify as transgender or gender diverse , and are currently using or are interested in using DMPA.

Exclusion Criteria

Any contraindications to DMPA (based on any category 3 or 4 recommendations from the CDC MEC guidelines)

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT05726903). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.